ADI-270, An Allogeneic Armored γδ CAR T-Cell Product with Potential to Address the Challenges of Targeting Solid Tumors

Time: 9:30 am
day: Post-Conference Solid Tumor Focus Day

Details:

• Share ADI-270 design and product characteristics
• Preclinical data supporting potential to overcome challenges in solid tumor targeting
• Discuss how ADI-270 is differentiated compared to conventional αβ CAR-T benchmarks

Speakers:

Shon Green